Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Major Indiana employer speaks out on state’s near-total abortion ban and vows to look outside state for ‘employment growth’

Pharmaceutical giant Eli Lilly is headquartered in Indianapolis and employs more than 10,000 people in the state

The Independent UK

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review

The stock market rally had mixed action, with the Nasdaq and small caps rising while the S&P 500 and oil prices fell.

Investors Business Daily

Eli Lilly Slashes Profit Outlook After 'Significantly' Missing Second-Quarter Forecasts

Eli Lilly Slashes Profit Outlook After 'Significantly' Missing Second-Quarter Forecasts

Eli Lilly slashed its 2022 earnings outlook Thursday after "significantly" missing forecasts, leading LLY stock to crumble.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Kerry Katona wants daughter Lily, 19, to have baby as she's worried about dying

Kerry says her “health anxiety” causes her to constantly worry about dying young and she would love for her teenage daughter Lilly to have a child of her own

Eli Lilly Stock Nears A New Buy Point

Pharmaceuticals giant Eli Lilly has formed a three-weeks tight pattern within the buy zone of flat base just before earnings.

Investors Business Daily

Michael Hiltzik: As professionals flee antiabortion policies, red states face a brain drain

A few days ago, a university headhunter reached out to Elizabeth T. Jacobs, a professor of epidemiology at the University of Arizona, to gauge her interest in moving to a leading university in Texas.

Los Angeles Times

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

inkl

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Futures Jump, Bitcoin Above $20,000; Beware The Bear Market

Dow Jones Futures Jump, Bitcoin Above $20,000; Beware The Bear Market

Futures rose as Bitcoin rebounded. It's a bear market, so stay safe. Tesla rival BYD is among a few stocks setting up.

Investors Business Daily

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy

Alopecia areata, an autoimmune disorder that causes patchy hair loss, now has a new treatment that has been approved by the Food and Drug Administration.

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit

A group of pharmaceutical stocks are climbing as they pivot their diabetes drugs to help treat obesity. A potential multibillion-dollar market beckons them.

Investors Business Daily

In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year

In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year

Eli Lilly And Co (NYSE:LLY) announced topline results from one-year analyses of the efficacy and safety of lebrikizumab for moderate-to-severe atopic dermatitis (AD). The new findings from the Phase 3 trials (ADvocate 1 and 2) showed that 8/10 of patients who achieved clinical response with lebrikizumab monotherapy at 16 weeks maintained skin clearance…

Eli Lilly Flirts With Buy Point On A 'Flawless' Update For Its Diabetes-Turned-Obesity Drug

Eli Lilly Flirts With Buy Point On A 'Flawless' Update For Its Diabetes-Turned-Obesity Drug

Eli Lilly delivered a promising update for its experimental obesity treatment over the weekend, leading LLY stock to pop Monday.

Investors Business Daily

Option Trade Benefits From Steady Action In Eli Lilly Stock

Option Trade Benefits From Steady Action In Eli Lilly Stock

The ideal scenario for this Lilly stock option trade for the stock to stay between 300 and 335 for the next two weeks.

Investors Business Daily

Executives Sell Over $100M Of 4 Stocks

Executives Sell Over $100M Of 4 Stocks

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Why Leaderboard And IBD 50 Stock Eli Lilly Just Became Actionable

Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review

A newly confirmed stock market rally immediately came under heavy pressure as Walmart and Target warnings slammed the major indexes.

Investors Business Daily

Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster

The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Is Eyeing Not One — But Two — Multibillion-Dollar Opportunities

Eli Lilly is the IBD Stock Of The Day after "transformative" data in obesity helped LLY stock retain its recent breakout.

Investors Business Daily

IBD 50 Stocks To Watch: Medical Stock Eli Lilly Trades In Buy Zone After Reporting Promising Q1 Results

With several core products showing strength, along with their Covid-19 antibodies, Eli Lilly updated their 2022 EPS guidance.

Investors Business Daily

Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review

A market rally attempt is underway, but the major indexes lost ground. Apple and Facebook led key earnings. Elon Musk will buy Twitter.

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Ulcerative Colitis

Places

256,069 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play